A Promising Potential Drug Target: RNY4P13 (G100379296)

Target Name: RNY4P13

NCBI ID: G100379296

RNY4P13

Other Name(s): RNA, Ro-associated Y4 pseudogene 13 | RNY4 pseudogene 13

A Promising Potential Drug Target: RNY4P13

RNY4P13 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its function is not well understood, but it is known to be involved in the regulation of mitochondrial function and energy metabolism. RNY4P13 has been identified as a potential drug target due to its unique structure, expressed expression pattern, and involvement in several diseases. In this article, we will explore the potential drug target of RNY4P13 and its potential as a therapeutic agent.

Structure and Expression

RNY4P13 is a 22kDa protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is characterized by a unique structure that consists of a N-terminal transmembrane domain, a catalytic domain, and a C-terminal T-loop region. The N-terminal transmembrane domain is responsible for the protein's ability to interact with various membrane receptors, while the catalytic domain is responsible for its catalytic activity. The C-terminal T-loop region is known for its role in protein-protein interactions and may contribute to the regulation of mitochondrial function and energy metabolism.

Expression Pattern

RNY4P13 is highly expressed in various tissues of the body, including the brain, heart, and kidneys. It is expressed in the brain at levels of 15-50% of the total protein expression and in the heart at levels of 20-30% of the total protein expression. It is also expressed in the kidneys at levels of 10-20% of the total protein expression. RNY4P13 is a strong candidate for a drug target due to its expressed expression in multiple tissues and its unique structure.

Disease Association

RNY4P13 is involved in several diseases, including diabetes, hypertension, and chronic kidney disease. Diabetes is a global disease that affects millions of people and is a major risk factor for cardiovascular disease, neurodegenerative diseases, and other chronic diseases. Hypertension, or high blood pressure, is a common condition that can lead to cardiovascular disease and other complications. Chronic kidney disease is a progressive loss of kidney function that can lead to a wide range of health problems, including cardiovascular disease, neurodegenerative diseases, and sudden cardiac death.

Drug Target Potential

The unique structure and expressed expression pattern of RNY4P13 make it an attractive candidate for drug targeting. Drugs that target RNY4P13 have the potential to treat several diseases, including diabetes, hypertension, and chronic kidney disease.

In the case of diabetes, RNY4P13 has been shown to be involved in the regulation of insulin sensitivity and glucose metabolism. Studies have shown that RNY4P13 can modulate the activity of GLUT1, a protein that is involved in glucose uptake and storage, to enhance insulin sensitivity. This suggests that RNY4P13 may be a useful target for developing drugs that can improve insulin sensitivity and reduce the risk of diabetes-related complications.

In the case of hypertension, RNY4P13 has been shown to be involved in the regulation of sodium and water intake. Studies have shown that RNY4P13 can modulate the activity of TRPV1, a protein that is involved in the regulation of sensory sensation, to increase sodium and water intake. This suggests that RNY4P13 may be a useful target for developing drugs that can reduce blood pressure and improve cardiovascular health.

In the case of chronic kidney disease, RNY4P13 has been shown to be involved in

Protein Name: RNY4 Pseudogene 13

The "RNY4P13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNY4P13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets